News and Trends 3 May 2018 World’s First Gene Therapy Developer Raises $128M for Hemophilia and Huntington’s uniQure has raised a substantial public offering on the NASDAQ. The funding could help the Dutch biotech advance two new gene therapies after the withdrawal of its first treatment. Amsterdam-based uniQure has raised an ambitious $128M (€107M) in a public offering at the beginning of next week. The Dutch biotech develops gene therapies for hemophilia and Huntington’s disease, for […] May 3, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
More News! 28 Feb 2018 Could A More Precise CRISPR/Cas9 System Treat Huntington’s Disease? Polish researchers tested a new variant of CRISPR/Cas9 that increases the gene-editing system’s precision in targeting specific DNA sequences, such as the gene responsible for Huntington’s disease. CRISPR/Cas9 offers a means of editing genes by essentially ‘cutting and pasting’ sequences of DNA. A group of researchers at the Institute of Bioorganic Chemistry in Poland has developed […] February 28, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 28 Feb 2018 Like Finding a Needle in a Haystack: How Are Biotechs Fighting Rare Diseases? Rare diseases affect fewer than 1 in 2,000 people in Europe and less than 200,000 Americans at any given time. A lack of financial incentive has put pharma off but biotechs are keen to step in and develop treatments and cures. Over 6,000 rare diseases affect up to 30 million people in the EU alone, which highlights […] February 28, 2018 - 8 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Best in Biotech 27 Dec 2017 The Biggest Biotech News of 2017: What Happened This Year? Still catching up on news? We’ve picked out the most exciting things that happened besides clinical results and finance. Here’s the biggest biotech news of 2017. We’ve been recapping the year with the most stellar biotechs, most heartening clinical successes and most disappointing failures in biotech. But what else happened this year? There’s more news […] December 27, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2017 This Gene Therapy for Hemophilia Can Reduce Bleeding by 70% UniQure has published clinical data revealing that its gene therapy for hemophilia B is effective for years and lets patients stop weekly replacement therapy. From its headquarters in Amsterdam, uniQure is developing what could be one of the first gene therapies for hemophilia. A publication in the journal Blood yesterday details the results of a […] December 19, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 28 Nov 2017 Reviewing Gene Therapy: How Close is Biotech to Genetic Cures? Over 10,000 human diseases are caused by exactly one faulty gene. Gene therapy promises to fix each of them. Here’s a review of biotech’s progress. Biotech is arguably built on genetic medicine. When Genentech‘s insulin produced by genetically engineered bacteria kicked off biotech fever in the 1980s, the concept of directly repairing defective human DNA wasn’t […] November 28, 2017 - 8 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2017 Close to Launching Gene Therapy, Dutch Biotech Raises Over $91M on the Nasdaq Update (2/11/2017): uniQure has closed its public offering raising over $91m (€78M) on the Nasdaq, taking advantage of a massive stock jump triggered by the announcement that an improved version of its gene therapy for hemophilia B will enter Phase III trials. Originally published on 24/10/2017 UniQure launched a public offering, perfectly timed with a rise in […] November 2, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2017 Dutch Biotech plans Pivotal Clinical Trial with First Gene Therapy for Hemophilia uniQure is getting ready to start a Phase III clinical trial in 2018 with a new version of its gene therapy for hemophilia B. uniQure has officially launched a plan to bring the first gene therapy for hemophilia to the market. After multiple meetings with the FDA and the EMA, the Dutch biotech has received permission […] October 19, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 26 Sep 2017 These Three Fields Are Proving Biotech is The Innovation Powerhouse in Healthcare Biotech is the best source of innovation in R&D, making its companies the darlings of pharma. Which therapeutic fields belong to biotech? “Biotech is typically first in highly innovative fields,” Matt Kapusta, CEO of uniQure told us. Before he became CEO, uniQure brought the world’s first gene therapy to market — completely on its own. Biotech […] September 26, 2017 - 8 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 8 May 2017 Meet the co-developer of the first commercial mAb and gene therapy Sander van Deventer is now a managing partner at Forbion after playing a critical role in the development of the first commercial monoclonal antibody, Remicade, and the first market-approved gene therapy, Glybera. I was curious to know what he did to achieve such an impressive track record. Sander van Deventer was trained as an internist […] May 8, 2017 - 5 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 25 Apr 2017 EMA designates uniQure’s gene therapy for hemophilia a priority Following a Breakthrough Designation from the FDA earlier this year, the Dutch biotech has scored the European equivalent for AMT-060. Since its claim to fame, Glybera, fell from grace to become a commercial failure, uniQure has been on the rebound. The company recently has undergone several management shakeups and a strategy review, and it just made the decision to withdraw […] April 25, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 20 Apr 2017 Goodbye Glybera! The World’s First Gene Therapy will be Withdrawn The excitement about the therapy was undercut when it became clear Glybera would be a commercial failure. In October, it will officially be dead. uniQure has announced that it will not go for the renewal of its marketing authorization for Glybera in Europe, which is set to expire in October this year. Since Glybera missed approval in the […] April 20, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email